drugset
drugset / Trial / NCT03407144

Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)

NCT03407144 ↗

Phase 2 Active not recruiting 340 enrolled Merck Sharp & Dohme LLC
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will examine the safety and efficacy of pembrolizumab (MK-3475) in combination with chemotherapy in children and young adults with newly diagnosed classical Hodgkin Lymphoma (cHL) who are slow early responders (SERs) to frontline chemotherapy.

Timeline

Start
2018-04-09
Primary completion
2026-11-06
Completion
2026-11-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Pembrolizumab Monoclonal antibody 2 mg/kg Intravenous
Subject Pembrolizumab Monoclonal antibody 200 mg Intravenous
Background Bleomycin Unknown 10 unknown Intravenous
Background Cyclophosphamide Other / unclassified 500 mg/m2 Intravenous
Background Dacarbazine Small molecule 250 mg/m2 Intravenous
Background Dacarbazine Small molecule 375 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 25 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 40 mg/m2 Intravenous
Background Etoposide Small molecule 125 mg/m2 Intravenous
Background Prednisolone Other / unclassified 40 mg/m2 Oral
Background Prednisolone Other / unclassified 60 mg/m2 Oral
Background Prednisone Other / unclassified 40 mg/m2 Oral
Background Prednisone Other / unclassified 60 mg/m2 Oral
Background Vinblastine Small molecule 6 mg/m2 Intravenous
Background Vincristine Small molecule 1.5 mg/m2 Intravenous

Indications

classic Hodgkin lymphoma